Eli Lilly Engages in Advanced Talks to Acquire Ventyx Biosciences for Over $1 Billion

Eli Lilly is in advanced discussions to purchase Ventyx Biosciences for over $1 billion, according to a Wall Street Journal report. The news prompted a 5.2% rise in Ventyx's share price, reflecting investor confidence.

洞察:
Eli Lilly and Company is reportedly in advanced negotiations to acquire Ventyx Biosciences Inc for a sum exceeding $1 billion. This development was revealed by the Wall Street Journal on January 6, 2026, citing sources familiar with the matter. Following the report, Ventyx's share price surged by 5.2%, indicating a positive market reaction and investor confidence in the potential transaction.
FILE PHOTO: The Eli Lilly logo is displayed on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake//File Photo
FILE PHOTO: The Eli Lilly logo is displayed on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake//File Photo
IUX24

IUX24 提供深度財經、經濟與投資資訊,藉助 AI 發掘全球市場中最重要的信號。

IFZA Properties, Dubai Silicon Oasis, DSO-IFZA, Dubai, United Arab Emirates

Copyright IUX24 MEDIA - FZCO. 版權所有。

由 AI 驅動 • 精益求精

IUX24 是一個資訊與分析平台,提供新聞、市場數據、分析工具及 AI 驅動的功能,僅供資訊參考與教育用途。所提供的服務和資訊不構成投資建議、交易信號或經紀服務。投資涉及風險,用戶在作出投資決定前應審慎評估相關資訊。